Physician profile
Emily E Geise-Smith
NPI 1538624978
$3,149.45
in general payments reported to CMS, 2019-2025
22 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $110 · 2023: $900 · 2024: $859 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.35 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $467.72 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $364.16 | 2023-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $258.62 | 2021-2025 | |
| Madrigal Pharmaceuticals | $225.88 | 2025 | Rezdiffra |
| Ardelyx, INC. | $171.07 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $162.82 | 2023-2025 | Stelara, Simponi Aria, Simponi |
| Ironwood Pharmaceuticals, INC | $112.11 | 2022-2024 | Linzess |
| Pfizer INC. | $51.46 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $47.03 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $46.74 | 2024-2025 | Omvoh |
| Celgene Corporation | $46.38 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $45.32 | 2023-2024 | Ocaliva |
| Amgen INC. | $34.66 | 2024-2025 | Repatha |
| Nestle Healthcare Nutrition INC. | $33.69 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $27.63 | 2025 | Vegzelma |
| Exact Sciences Corporation | $27.49 | 2025 | The Cologuard Plus Collection Kit |
| Fresenius Kabi USA, LLC | $26.31 | 2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $24.81 | 2024 | Terlivaz |
| Braintree Laboratories, INC. | $18.79 | 2023 | Sutab |
| Ferring Pharmaceuticals INC. | $16.44 | 2023 | Rebyota |
| Qol Medical, LLC | $15.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Geise-Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.